Valeant Pharmaceuticals Intl Inc.: 3 More Game-Changing Updates

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) likes to keep investors guessing.

The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shocked the markets once again on Monday with a press release containing three interesting updates.

We take a look at each of them below.

1. Michael Pearson is returning

Michael Pearson will be resuming his role as CEO, effective immediately, according to the release. He had stepped aside at the end of December due to a severe case of pneumonia as well as other medical complications.

Mr. Pearson’s return is a mixed blessing for the company. On the one hand, Mr. Pearson successfully built the company into the pharmaceutical behemoth that it is today. Nomura Securities analyst Shibani Malhotra even said that Valeant would lose its competitive advantage without Mr. Pearson and that the company should consider selling itself in such a scenario.

On the other hand, Mr. Pearson is also associated with all of Valeant’s recent troubles, which could make him somewhat of a lightning rod. Worse still, he is not particularly comfortable in the spotlight; public speaking is not his strong suit. To top it all off, Mr. Pearson’s biggest strength–identifying the right acquisition targets–isn’t nearly as relevant today as it had been in the past.

2. Delaying results

Given the timing of Mr. Pearson’s return, Valeant is delaying the reporting of its fourth-quarter results. At least that’s what it says in the press release. But this smells very fishy. After all, Mr. Pearson couldn’t have waited a few days to return? It’s not as if the company needs him back immediately.

3. Restating guidance

In addition to delaying fourth-quarter results, Valeant is also pulling its guidance for the year 2016. This raises even more suspicions than the delayed results because Mr. Pearson’s return should have no effect on the company’s guidance.

To put it bluntly, the delayed results and pulled guidance probably have more to do with each other than Valeant would like to admit. And I personally don’t believe that Mr. Pearson’s return is what caused these issues.

There is one other possible explanation. When Mr. Pearson went on medical believe, Valeant bears speculated that he didn’t want his signature on the company’s latest filings. So Valeant’s decision on Monday could simply be an attempt to refute those criticisms. And if that is indeed the case, then the fall in its share price may be unwarranted.

But let’s not forget that this is a company with some serious credibility issues already. Thus it shouldn’t be surprising that investors aren’t buying the company’s latest explanation. And this is a stock you should definitely stay away from, no matter how cheap it looks.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »